COPD Respiratory Chronic obstructive pulmonary disease, unspecified
Conditions
Interventions
Treatment will with 10mg enalapril or matched placebo once daily. Drug and placebo will be encapsulated by Royal Free Pharmacy. Drug will be dispensed from the pharmacy at Royal Brompton and Harefield
Sponsors
Imperial College London (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Adults with GOLD stage II-IV COPD and a clinical indication for pulmonary rehabilitation (MRC score of 3 or more or functionally limited)
Exclusion criteria
Exclusion criteria: 1. Clinically unstable patients (within one month of exacerbation) 2. Those with a permanent pacemaker (which is a contraindication to magnetic stimulation), or significant co-morbidity 3. Patients with an accepted indication for ACE inhibition (left ventricular dysfunction, diabetes) or a contraindication such as renovascular disease 4. Creatinine clearance (estimated) <50) 5. Hypotension 6. Use of anticoagulants (contra-indication to biopsy) or ACE-I or ATII receptor antagonists 7. Allergy to ACE-inhibitors 8. Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Increase in peak workload achieved on a cycle ergometer following a rehabilitation program compared between enalapril and placebo treated patients. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Quadriceps strength 2. Six minute walk distance 3. HRQOL (CAT score) 4. Physical activity level (SenseWear armband) | — |
Countries
United Kingdom
Outcome results
None listed